Citation
Roberts, J L., et al. "Clinical Dose Ranging Studies With Finasteride, a Type 2 5alpha-reductase Inhibitor, in Men With Male Pattern Hair Loss." Journal of the American Academy of Dermatology, vol. 41, no. 4, 1999, pp. 555-63.
Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41(4):555-63.
Roberts, J. L., Fiedler, V., Imperato-McGinley, J., Whiting, D., Olsen, E., Shupack, J., Stough, D., DeVillez, R., Rietschel, R., Savin, R., Bergfeld, W., Swinehart, J., Funicella, T., Hordinsky, M., Lowe, N., Katz, I., Lucky, A., Drake, L., Price, V. H., ... Gencheff, C. (1999). Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology, 41(4), 555-63.
Roberts JL, et al. Clinical Dose Ranging Studies With Finasteride, a Type 2 5alpha-reductase Inhibitor, in Men With Male Pattern Hair Loss. J Am Acad Dermatol. 1999;41(4):555-63. PubMed PMID: 10495375.
TY - JOUR
T1 - Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.
A1 - Roberts,J L,
AU - Fiedler,V,
AU - Imperato-McGinley,J,
AU - Whiting,D,
AU - Olsen,E,
AU - Shupack,J,
AU - Stough,D,
AU - DeVillez,R,
AU - Rietschel,R,
AU - Savin,R,
AU - Bergfeld,W,
AU - Swinehart,J,
AU - Funicella,T,
AU - Hordinsky,M,
AU - Lowe,N,
AU - Katz,I,
AU - Lucky,A,
AU - Drake,L,
AU - Price,V H,
AU - Weiss,D,
AU - Whitmore,E,
AU - Millikan,L,
AU - Muller,S,
AU - Gencheff,C,
PY - 1999/9/25/pubmed
PY - 1999/9/25/medline
PY - 1999/9/25/entrez
SP - 555
EP - 63
JF - Journal of the American Academy of Dermatology
JO - J Am Acad Dermatol
VL - 41
IS - 4
N2 - BACKGROUND: Androgenetic alopecia is a common condition of adult men. Finasteride, a type 2 5alpha-reductase inhibitor, decreases the formation of dihydrotestosterone from testosterone. OBJECTIVE: Two separate clinical studies were conducted to establish the optimal dose of finasteride in men with this condition. METHODS: Men from 18 to 36 years of age with moderate vertex male pattern hair loss received finasteride 5, 1, 0.2, or 0.01 mg/day or placebo based on random assignment. Efficacy was determined by scalp hair counts, patient self-assessment, investigator assessment, and assessment of clinical photographs. Safety was assessed by clinical and laboratory measurements and by analysis of adverse experiences. RESULTS: Efficacy was demonstrated for all end points for finasteride at doses of 0.2 mg/day or higher, with 1 and 5 mg demonstrating similar efficacy that was superior to lower doses. Efficacy of the 0.01 mg dose was similar to placebo. No significant safety issues were identified in the trials. CONCLUSION: Finasteride 1 mg/day is the optimal dose for the treatment of men with male pattern hair loss and was subsequently identified for further clinical development.
SN - 0190-9622
UR - https://www.unboundmedicine.com/medline/citation/10495375/Clinical_dose_ranging_studies_with_finasteride_a_type_2_5alpha_reductase_inhibitor_in_men_with_male_pattern_hair_loss_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190-9622(99)80052-8
DB - PRIME
DP - Unbound Medicine
ER -
